# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066413
Filing Date
2025-05-08
Accepted
2025-05-08 08:00:20
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nams-20250331.htm iXBRL | 10-Q | 2092541
2 | EX-31.1 | nams-ex31_1.htm | EX-31.1 | 17379
3 | EX-31.2 | nams-ex31_2.htm | EX-31.2 | 17336
4 | EX-32.1 | nams-ex32_1.htm | EX-32.1 | 9596
5 | EX-32.2 | nams-ex32_2.htm | EX-32.2 | 9570
| Complete submission text file | 0000950170-25-066413.txt |  | 8167572

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nams-20250331.xsd | EX-101.SCH | 1284070
71 | EXTRACTED XBRL INSTANCE DOCUMENT | nams-20250331_htm.xml | XML | 1294217

Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41562 | Film No.: 25923958
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)